Cat. No：GM-88011MAB
Product：Anti-CD3E×BCMA hIgG4 Reference Antibody (Tecbio)
Cat. No：GM-88011MAB
Product：Anti-CD3E×BCMA hIgG4 Reference Antibody (Tecbio)
GM-88011MAB-1mg / 1 mg
GM-88011MAB-5mg / 5 mg
GM-88011MAB-25mg / 5 mg * 5 vials
GM-88011MAB-50mg / 50 mg
GM-88011MAB-100mg / 50 mg * 2 vials
Expression System | CHO |
Aggregation | < 5% as determined by SEC-HPLC |
Purity | > 95% as determined by SDS-PAGE |
Species Reactivity | Human |
Clone | teclistamab |
Source/Isotype | Monoclonal Human hIgG4 (S228P/F234A/L235A) λ-2 |
Application | Flow Cytometry; Aassay |
Specificity | Detects CD3E & BCMA |
Gene | CD3E & BCMA |
Other Names | CD3E: CD3epsilon, IMD18, T3E, TCRE |
BCMA: BCM, TNFRSF17, CD269, TNFRSF13A | |
Background | Teclistamab is a Bispecific monoclonal antibody that enhances the immune system's ability to attack cancer cells by targeting two different antigens at once. It specifically binds to B cell maturation antigen (BCMA) and CD3 molecules on the surface of T cells, forming a“Bridge” that enables T cells to recognize and contact myeloma cells more efficiently. When Teclistamab binds to CD3, it activates T cells, prompting them to release cytokines that mediate the killing of tumor cells and thus promote their death. In addition, Teclistamab directs T cells to the tumor microenvironment, further enhancing the body's anti-tumor immune response. This mechanism dramatically improves the effectiveness of Teclistamab in treating multiple myeloma. |
Storage | Store at 2-8°C short term (1-2 weeks). Store at ≤ -20°C long term.Avoid repeated freeze-thaw. |
Formulation | Phosphate-buffered solution, pH 7.2-7.4. |
Cat. No：GM-88011MAB
Product：Anti-CD3E×BCMA hIgG4 Reference Antibody (Tecbio)
GM-88011MAB-1mg / 1 mg
GM-88011MAB-5mg / 5 mg
GM-88011MAB-25mg / 5 mg * 5 vials
GM-88011MAB-50mg / 50 mg
GM-88011MAB-100mg / 50 mg * 2 vials
Expression System | CHO |
Aggregation | < 5% as determined by SEC-HPLC |
Purity | > 95% as determined by SDS-PAGE |
Species Reactivity | Human |
Clone | teclistamab |
Source/Isotype | Monoclonal Human hIgG4 (S228P/F234A/L235A) λ-2 |
Application | Flow Cytometry; Aassay |
Specificity | Detects CD3E & BCMA |
Gene | CD3E & BCMA |
Other Names | CD3E: CD3epsilon, IMD18, T3E, TCRE |
BCMA: BCM, TNFRSF17, CD269, TNFRSF13A | |
Background | Teclistamab is a Bispecific monoclonal antibody that enhances the immune system's ability to attack cancer cells by targeting two different antigens at once. It specifically binds to B cell maturation antigen (BCMA) and CD3 molecules on the surface of T cells, forming a“Bridge” that enables T cells to recognize and contact myeloma cells more efficiently. When Teclistamab binds to CD3, it activates T cells, prompting them to release cytokines that mediate the killing of tumor cells and thus promote their death. In addition, Teclistamab directs T cells to the tumor microenvironment, further enhancing the body's anti-tumor immune response. This mechanism dramatically improves the effectiveness of Teclistamab in treating multiple myeloma. |
Storage | Store at 2-8°C short term (1-2 weeks). Store at ≤ -20°C long term.Avoid repeated freeze-thaw. |
Formulation | Phosphate-buffered solution, pH 7.2-7.4. |
